NCT00788177Unknown3 期
Subretinal Macugen® for Neovascular Age-Related Macular Degeneration (SUMANA)
Klinikum Ludwigshafen2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2008年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks
研究概览
简要总结
The purpose of this study is to assess the efficacy of pegaptanib (Macugen®) for neovascular (exudative) age-related macular degeneration (AMD) when the first dose is administered to the submacular space instead of vitreous body in cases when previous state-of-the-art treatment for the AMD was deemed ineffective.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults aged 50 years and older with neovascular AMD proven by FA
- •Patients who at baseline
- •Have a BCVA letter score in the study eye between 20/40 to 20/320 using an ETDRS chart measured at 4 meters or Snellen equivalent
- •Have a CNV lesion of any type in the study eye with the following characteristics as determined by fluorescein angiography:
- •Evidence that CNV extends under the geometric center of the foveal avascular zone.
- •Previous state-of-the-art therapy for the disease is deemed ineffective with following characteristics are given:
- •Loss of visual acuity (2 or more Snellen lines) in the previous 3 months defined as either OR
- •≥10% increase in the lesion diameter as assessed by fluorescein angiography in the previous 3 months
- •Ability of subject to understand character and individual consequences of clinical trial.
- •Signed and dated informed consent of the subject must be available before start of any specific trial procedures.
- •Women with childbearing potential practicing a medically accepted contraception (negative pregnancy test result, serum or urine at trial entry).
排除标准
- •Subjects presenting with any of the following criteria will not be included in the trial:
- •Have a relevant ocular disease which may be associated with increased intraocular VEGF levels (namely uveitis, neovascular glaucoma, diabetic retinopathy, diabetic maculopathy, ocular ischemic syndrome, retinal vessel occlusion)
- •Had previous vitrectomy surgery for whatsoever reason
- •Are not pseudophakic
- •Have a >50% area of scarring of the whole CNV lesion size as seen in FA
- •Arterial hypertension refractory to medical treatment
- •Pregnancy and lactation.
- •History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.
- •Participation in other clinical trials during the present clinical trial or within the last 3 months.
- •Medical or psychological condition that would not permit completion of the trial or signing of informed consent.
- •Suspected or present ocular or periocular infection
结局指标
主要结局
Proportion of patients who had lost fewer than 15 letters of visual acuity at 54 weeks
时间窗: 54 weeks
Mean change from baseline in total size of lesion and total size of CNV at 12, 24 and 54 weeks
时间窗: week 24 and 54
次要结局
- Changes in best corrected visual acuity (BCVA) from baseline at 54 weeks(54 weeks)
- Mean change from baseline in at week 12 and 24(week 12 and 24)
- Proportion of patients who gain ≥ 5, 10, 15 letters of BCVA from baseline at week 24 and 54(week 24 and 54)
- Proportion of patients who lose less than 15 letters of BCVA from baseline at week 24 and 54(week 24 and 54)
- Change in area of leakage at 12, 24 and 54 weeks(weeks 12, 24 and 54)
- Mean change in retinal thickness by OCT at center of fovea at 12, 24 and 54 weeks(weeks 12, 24 and 54)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
Subretinal Macugen for neovascular age-related macular degeneration (SUMANA) - SUMANAeovascular (exudative) age-related macular degenerationMedDRA version: 9.1Level: LLTClassification code 10015902Term: Exudative senile macular degeneration of retinaEUCTR2007-006290-90-DESociety (Institute) for clinical research
已完成
不适用
A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.Neovascular Age-related Macular DegenerationNCT00549055Pfizer38
已完成
2 期
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular DegenerationMacular DegenerationNCT02181517Allergan25
已完成
1 期
A Pilot Study for the Treatment of Iris Neovascularization With MacugenIris NeovascularizationDiabetic RetinopathyNCT00295828Hermann Eye Center10
进行中（未招募）
不适用
Treatment of neovascular age related macular degeneration with intravitreal Bevacizumab (Avastin)neovascular age-related macular degenerationEUCTR2006-001914-34-DEBert Mueller, Dep. Ophthalmology